Core Product Advantages

1. High Efficiency and Accuracy

Adopts high-precision next-generation sequencing technology to detect related genes with high sensitivity and accuracy, and efficiently completes the whole detection and analysis process, ensuring the reliability and timeliness of test results for clinical medication guidance.

1. Authoritative Guidance

Based on authoritative pharmacogenomic research evidence and clinical medication guidelines, the test results provide professional and authoritative reference for clinical rational drug use, helping to avoid blind medication and improve the scientificity of medication plans.

1. Convenient Operation

Features a streamlined and standardized detection process, with simple sample collection and experimental operation steps, easy to implement in clinical institutions, and suitable for large-scale clinical testing and personalized medication assessment scenarios.

Key Detection Content

This product comprehensively analyzes 55 core genes that are closely associated with 80 common antipsychotic and antineurological medications. Through the detection and analysis of these pharmacogenomic markers, it can accurately predict the therapeutic efficacy of the above drugs for individual patients and the potential risk of adverse drug reactions, and provide targeted medication suggestions for different patients.

Applicable Population

1. Patients taking antipsychotic and antineurological drugs for the first time
2. Patients taking multiple mental/neurological drugs simultaneously or for an extended period
3. Patients who have an unsatisfactory therapeutic response to a specific antipsychotic or antineurological drug
4. Patients who have experienced drug adverse reactions themselves or with a family history of such reactions
5. Special groups with medication risks (those with impaired liver or kidney function, the elderly, children, etc.)
6. People with mental/neurological diseases who prioritize safe and rational medication

Clinical Significance

1. Individualized Precision Medicine

From the genetic level, it clarifies the individual drug response characteristics of patients with mental and neurological diseases, and helps clinicians formulate personalized and targeted precise medication plans, realizing the transformation from empirical medication to precision medication.

1. Reference for Clinical Rational Drug Use

Provides professional pharmacogenomic reference for clinical medication decision-making, helps avoid irrational medication behaviors such as inappropriate drug selection and dosage, and standardizes the clinical medication process for mental and neurological diseases.

1. Improve Drug Therapeutic Efficacy

Accurately predicts the drugs with good therapeutic effect for individual patients, helps clinicians select the most suitable first-line medication, and improves the overall therapeutic effect of antipsychotic and antineurological treatments.

1. Reduce the Risk of Adverse Drug Reactions

Identifies patients with high risk of adverse drug reactions in advance, and guides clinicians to avoid high-risk drugs or adjust medication dosage in a timely manner, reducing the occurrence of drug-induced injuries and improving the safety of clinical medication.

Standard Detection Process

1. Informed consent signing
2. Clinical sample collection
3. Nucleic acid extraction and quality control
4. Gene library preparation
5. Next generation sequencing (based on self-developed sequencer)
6. Professional pharmacogenomic data analysis
7. Formal test report distribution

Rapid Lead Time

The whole detection and analysis process is highly efficient, and the professional pharmacogenomic test report can be completed and released within 7 to 10 working days after receiving qualified samples, ensuring the timeliness of clinical precise medication decision-making.